Drug screening identifies the Src/Abl inhibitor Dasatinib as suppressor of IL-23 signalling in skin inflammation
M.J. Valle-Pastor, I. Cayuela, J.S. Yebra, L. Senach-Rasilla, Gloria Pastor-Fernández, Aurea Oliva, Javier Traba, MN Rayo Navarro
The paper identifies Dasatinib as a suppressor of IL-23 signaling in skin inflammation by blocking mTORC1 and mTORC2 activation in γδ17 T cells.
Journal of Allergy and Clinical Immunology · Mar 9, 2026Peer-reviewedImmunology